



# Construction of an l-Tyrosine Chassis in *Pichia pastoris* Enhances Aromatic Secondary Metabolite Production from Glycerol

Kumokita, Ryota ; Bamba, Takahiro ; Inokuma, Kentaro ; Yoshida, Takanobu ; Ito, Yoichiro ; Kondo, Akihiko ; Hasunuma, Tomohisa

---

**(Citation)**

ACS Synthetic Biology, 11(6):2098-2107

**(Issue Date)**

2022-06-17

**(Resource Type)**

journal article

**(Version)**

Accepted Manuscript

**(Rights)**

This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Synthetic Biology, copyright © 2022 American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see <https://pubs.acs.org/articlesonrequest/AOR-9VJ2URZZ4RYMINYJZKWB>

**(URL)**

<https://hdl.handle.net/20.500.14094/0100476927>



1 **TITLE:** Construction of an L-Tyrosine chassis in *Pichia pastoris* enhances aromatic  
2 secondary metabolites production from glycerol

3  
4 **AUTHORS:**

5 Ryota Kumokita, Takahiro Bamba, Kentaro Inokuma, Takanobu Yoshida,  
6 Yoichiro Ito, Akihiko Kondo, Tomohisa Hasunuma\*


7  
8 **ABSTRACT**

9 Bioactive plant-based secondary metabolites such as stilbenoids, flavonoids,  
10 and benzyloquinoline alkaloids (BIAs) are produced from L-Tyrosine (L-Tyr) and have  
11 a wide variety of commercial applications. Therefore, building a microorganism with  
12 high L-Tyr productivity (L-Tyr chassis) is of immense value for large scale production of  
13 various aromatic compounds. The aim of this study was to develop an L-Tyr chassis in  
14 the non-conventional yeast *Pichia pastoris* (*Komagataella phaffii*) to produce various  
15 aromatic secondary metabolites (resveratrol, naringenin, norcochlorine, and reticuline).  
16 Overexpression of feedback-inhibition insensitive variants of 3-deoxy-D-arabino-  
17 heptulosonate-7-phosphate synthase (*ARO4<sup>K229L</sup>*) and chorismate mutase (*ARO7<sup>G141S</sup>*)  
18 enhanced L-Tyr titer from glycerol in *P. pastoris*. These engineered *P. pastoris* strains  
19 increased the titer of resveratrol, naringenin, and norcochlorine by 258%, 244%, and  
20 3400%, respectively after expressing the corresponding heterologous pathways. The  
21 titer of resveratrol and naringenin further increased by 305% and 249% resulting in  
22 yields of 1825 mg/L and 1067 mg/L, respectively in fed-batch fermentation which is the  
23 highest titer from glycerol reported to date. Furthermore, the resveratrol-producing  
24 strain accumulated intermediates in the shikimate pathway. L-Tyr-derived aromatic  
25 compounds were produced using crude glycerol by-product from biodiesel fuel (BDF)  
26 production. Constructing L-Tyr chassis is a promising strategy to increase the titer of  
27 various aromatic secondary metabolites and *P. pastoris* is an attractive host for high

28 yield production of L-Tyr-derived aromatic compounds from glycerol.

29

30 **GRAPHICAL ABSTRACT**



31

32 **KEYWORDS**

33 aromatic secondary metabolite, L-Tyrosine chassis, *Pichia pastoris*, non-conventional

34 yeast, metabolomics, crude glycerol

35

## 36 INTRODUCTION

37 Plant-derived aromatic compounds are widely used as pharmaceutical drugs,  
38 dietary supplements, and nutraceuticals<sup>1-3</sup>. The production of these compounds  
39 predominantly relies on costly and inefficient extraction methods from low productivity  
40 plants<sup>4-6</sup>. Chemosynthesis does not improve productivity because of the complicated  
41 processes, strict reaction conditions, and poor selectivity<sup>7,8</sup>. Microbial production with  
42 reconstituted plant biosynthetic pathways has received increasing attention to ensure a  
43 sustainable supply of useful aromatic compounds and meet future anticipated  
44 demands<sup>9,10</sup>.


45 The aromatic amino acid L-Tyrosine (L-Tyr) is a building block to produce  
46 stilbenoids, flavonoids, and benzyloquinoline alkaloids (BIAs) in many plants. Thus,  
47 optimization of L-Tyr supply is important for producing L-Tyr-derived aromatic  
48 compounds in quantities that compete with commercial demands<sup>11</sup> and engineering  
49 microorganisms for L-Tyr overproduction is extensively studied<sup>12-14</sup>. For example,  
50 *Saccharomyces cerevisiae* has been genetically engineered for aromatic compound  
51 production<sup>15-17</sup>. Although *S. cerevisiae* is the preferred host due to its robustness and  
52 high stress tolerance during fermentation<sup>12</sup>, repression of ethanol production to produce  
53 aromatic compounds in high yield is difficult<sup>18</sup>. Hence, exploring alternative yeast  
54 platforms is of immense value.

55 The metabolism of Crabtree-negative yeasts such as *Yarrowia lipolytica* and  
56 *Pichia pastoris* (*Komagataella phaffii*) does not divert carbon flux to ethanol, and  
57 carbon partitioning among the various pathways is well balanced<sup>14</sup>. Recently, the yield  
58 of aromatic compounds using *Y. lipolytica* greatly increased compared to that of *S.*  
59 *cerevisiae*<sup>19,20</sup> suggesting productivity differs among microbial hosts. *P. pastoris* is  
60 widely used as a chassis to produce heterologous proteins for research and industrial  
61 purposes<sup>21,22</sup> which does not produce fermentative by-products under aerobic conditions  
62 because its glycolytic flux does not exceed the respiratory capacity<sup>23,24</sup>. Glycerol is

63 often used as a carbon source during *P. pastoris* fermentation because it encodes four  
64 H<sup>+</sup>/glycerol symporters in its genome allowing for efficient metabolism and high  
65 biomass productivity<sup>24-26</sup>. Glycerol requires fewer enzymatic reactions for the  
66 biosynthesis of phosphoenolpyruvate (PEP) from glycolysis and erythrose-4-phosphate  
67 (E4P) from the pentose phosphate pathway (PPP) compared to glucose (Figure 1). PEP  
68 and E4P are essential precursors for L-Tyr biosynthesis.

69 In this study, an L-Tyr chassis was developed in *P. pastoris* by rational  
70 engineering to increase the titer of various L-Tyr-derived aromatic secondary  
71 metabolites. Initial screening utilized a simple betaxanthin fluorescence assay to search  
72 for the overexpression of target genes enhancing L-Tyr titer. The potential of the L-Tyr  
73 chassis to produce resveratrol, naringenin, norcochlorine, and reticuline from glycerol  
74 was investigated by co-expressing the required heterologous pathways (Figure 1).  
75 Furthermore, the metabolic responses of the engineered resveratrol-producing strains  
76 were investigated and the potential of *P. pastoris* to produce aromatic secondary  
77 metabolite from crude glycerol by-product of biodiesel fuel (BDF) was evaluated.

78



79 **Figure 1. Biosynthetic pathway of betaxanthin, resveratrol, naringenin,**  
80 **norcoclaurine, and reticuline in *P. pastoris*.** The native pathway in *P. pastoris* is  
81 represented by black and red arrows. The red arrow represents the overexpression of  
82 genes. The pathways to produce betaxanthin, resveratrol, naringenin, norcoclaurine, and  
83 reticuline are illustrated in yellow, green, blue, purple, and gray, respectively. The  
84 dashed arrows indicate multiple enzymatic steps. G6P: glucose-6-phosphate; F6P:  
85 fructose-6-phosphate; F1,6BP: fructose-1,6-bisphosphate; GAP: glyceraldehyde  
86 3-phosphate; 1,3PG: 1,3-bisphosphoglycerate; PEP: phosphoenolpyruvate; 6PGL:  
87 6-phosphogluconolactone; 6PG: 6-phosphogluconate; Ru5P: ribulose-5-phosphate;  
88 R5P: ribose-5-phosphate; Xu5P: xylulose-5-phosphate; S7P:  
89 sedoheptulose-7-phosphate; E4P: erythrose-4-phosphate; TCA cycle: tricarboxylic acid  
90 cycle; DAHP: 3-deoxy-D-arabinoheptulosonate 7-phosphate; EPSP:  
91 5-*O*-(1-carboxyvinyl)-3-phosphoshikimate; ZWF1: glucose-6-phosphate dehydrogenase  
92 from *P. pastoris*; SOL3: 6-phosphogluconolactonase from *P. pastoris*; TKL1:  
93 transketolase from *P. pastoris*; ARO4<sup>K229L</sup>: DAHP synthase (K229L) from

94 *Saccharomyces cerevisiae*; ARO7<sup>G141S</sup>: chorismate mutase (G141S) from *S. cerevisiae*;  
95 BvCYP<sup>W13L, F903L</sup>: Tyrosine hydroxylase (W13L, F903L) from *Beta vulgaris*; MjDOD:  
96 DOPA dioxygenase from *Mirabilis jalapa*; PpDODC: DOPA decarboxylase from  
97 *Pseudomonas putida*; CjNCS: norcochlorine synthase from *Coptis japonica*; HaTAL:  
98 Tyrosine ammonia-lyase from *Herpetosiphon aurantiacus*; At4CL: 4-coumarate CoA  
99 ligase from *Arabidopsis thaliana*; VvVST: resveratrol synthase from *Vitis vinifera*;  
100 HaCHS: chalcone synthase from *Hypericum androsaemum*; MsCHI: chalcone  
101 isomerase from *Medicago sativa*; Ps6OMT: 6-O-methyltransferase from *Papaver*  
102 *somniferum*; PsCNMT: coclorine N-methyltransferase from *P. somniferum*; EcNMCH:  
103 N-methylcoclorine hydroxylase from *Eschscholzia californica*; Ps4OMT:  
104 4'-O-methyltransferase from *P. somniferum*.

105


## 106 **RESULTS**

### 107 **Identification of optimal engineering based on betaxanthin fluorescence**

108 To search for overexpression target genes that contribute to enhance the L-Tyr  
109 titer in a high-throughput manner, we employed betaxanthin production pathway  
110 (Figure 1). Betaxanthin is an L-Tyr-derived yellow pigment emitting green fluorescence  
111 used to evaluate the strength of metabolic flux to L-Tyr. An engineered *P. pastoris* strain  
112 (CD strain) expressing the betaxanthin pathway was generated by introducing tyrosine  
113 hydroxylase from *Beta vulgaris* (BvCYP<sup>W13L, F309L</sup>) and DOPA dioxygenase from  
114 *Mirabilis jalapa* (MjDOD) to detect L-Tyr production (Figure 1) and identify target  
115 genes contributing to enhanced L-Tyr titer in a high-throughput manner. The yellow  
116 coloration and green fluorescence of CD strain indicated successful betaxanthin  
117 production (Figure 2, Supporting Figure S1). We targeted PPP and shikimate pathway  
118 genes to improve L-Tyr titer. In *S. cerevisiae*, transketolase (*TKL1*), feedback-inhibition  
119 insensitive variants of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase  
120 (*ARO4*<sup>K229L</sup>) and chorismate mutase (*ARO7*<sup>G141S</sup>) were common overexpression targets

121 to increase the titer of L-Tyr-derived aromatic compounds<sup>11,12</sup>. Overexpression of  
 122 6-gluconolactonase (*SOL3*) and glucose-6-phosphate dehydrogenase (*ZWF1*) has been  
 123 reported to enhance the flux to PPP in *P. pastoris*<sup>27</sup>. In this study, overexpression of  
 124 *TKL1*, *SOL3*, and *ZWF1* from *P. pastoris*, and/or *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> from *S.*  
 125 *cerevisiae* were introduced, respectively (Figure 1) using the CD strain (Table 1).

126 Measurement of fluorescence intensity in the engineered *P. pastoris* strains  
 127 indicated that overexpression of *TKL1*, *SOL3*, and *ZWF1* from the PPP pathway did not  
 128 have a statistically significant effect ( $p > 0.05$ ) on betaxanthin levels while  
 129 overexpression of *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> from the shikimate pathway in strain  
 130 CD47m enhanced betaxanthin fluorescence by 191% (Figure 2). However, expression  
 131 of these genes from both the PPP and shikimate pathways produced less betaxanthin  
 132 fluorescence than the CD47m strain (Figure 2). Therefore, overexpression of *ARO4*<sup>K229L</sup>  
 133 and *ARO7*<sup>G141S</sup> was employed to increase the titer of L-Tyr-derived aromatic compounds  
 134 in subsequent experiments.






135 **Figure 2. Betaxanthin fluorescence.** Relative fluorescence intensity of the CD strain  
136 expressing pentose phosphate pathway (PPP) genes (blue), shikimate pathway genes  
137 (orange), and both PPP and shikimate pathway genes (green) after 24 h incubation in  
138 YPG medium. Error bars represent the standard deviation of three independent  
139 biological samples. The strains used in this study are summarized in Table 1. Control: *P.*  
140 *pastoris* CBS7435  $\Delta$ *dnl4*  $\Delta$ *his4*; *CYP*, *DOD*, *TKL1*, *SOL3*, *ZWF1*, *ARO4*<sup>K229L</sup>, and  
141 *ARO7*<sup>G141S</sup> as stated in Figure 1. Statistical analysis was performed using EZR  
142 (two-tailed, two-sample unequal variance; \**p* < 0.05, \*\**p* < 0.005).

143

#### 144 **Resveratrol production from glycerol**

145 Downstream L-Tyr products resveratrol, naringenin, and norcoclaurine were  
146 tested in the following sections to determine if they are positively affected by increased  
147 L-Tyr production (Figure 1). A resveratrol-producing strain (T4V strain) was developed  
148 through the introduction of *Herpetosiphon aurantiacus* (*HaTAL*), 4-coumarate CoA  
149 ligase from *Arabidopsis thaliana* (*At4CL*), and stilbene synthase from *Vitis vinifera*  
150 (*VvVST*)<sup>28</sup> into a parent strain (*P. pastoris* CBS7435  $\Delta$ *dnl4*  $\Delta$ *his4*). Furthermore,  
151 *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> were co-overexpressed to produce the T4V-ARO47m strain.  
152 The T4V-ARO47m strain was slightly defective in cell growth (Supporting Figure S2)  
153 and produced 451 mg/L resveratrol compared with 126 mg/L for the T4V strain with a  
154 yield of 22.5 mg/g-glycerol consumed (Figure 3A). Resveratrol titer in the  
155 T4V-ARO47m strain was further tested using fed-batch fermentation in a jar fermenter  
156 (Figure 3B) with constant DO and pH levels, and feeding solution added at the specified  
157 time. Cell growth (OD<sub>600</sub>) plateaued after 72 h of fermentation, while the resveratrol  
158 titer continuously increased and reached 1825 mg/L with a yield of 16.6 mg/g-glycerol  
159 consumed after 120 h of fermentation which is an improvement of 305% compared to  
160 cultivation in flasks (Figure 3B) and is the highest resveratrol titer from glycerol  
161 reported to date (Supporting Table S1).




162 **Figure 3. Resveratrol production in engineered *P. pastoris* strains.** (A) Time course  
 163 of resveratrol production and glycerol consumption in YPG culture medium of  
 164 resveratrol-producing strains (T4V and T4V-ARO47m) and their parent strain  
 165 CBS7435  $\Delta dnl4 \Delta his4$  (Control). Error bars represent standard deviations of three  
 166 independent biological samples. The solid lines and dashed lines represent the  
 167 resveratrol titer and glycerol concentration, respectively. (B) Fed-batch fermentation of  
 168 the T4V-ARO47m strain in the jar fermenter. The feed was added from 24 to 96 h.  
 169 Error bars represent the standard deviation of two independent biological samples.

170

### 171 **Quantification of intracellular metabolites in engineered *P. pastoris* strains**

172 To investigate the metabolic responses by overexpressing *ARO4*<sup>K229L</sup> and  
 173 *ARO7*<sup>G141S</sup> in *P. pastoris*, the intracellular metabolites of the T4V, T4V-ARO47m, and  
 174 their parent strain (*P. pastoris* CBS7435  $\Delta dnl4 \Delta his4$ ) were extracted and quantified.  
 175 There was no difference in the accumulation of glycolysis and PPP compounds at the  
 176 beginning of glycerol consumption (24 h fermentation), except for an accumulation of  
 177 fructose-1,6-bisphosphate (F1,6BP), phosphoenolpyruvate (PEP), and  
 178 6-phosphogluconate (6PG) in T4V-ARO47m (Figure 4). Meanwhile, intermediates of  
 179 the shikimate pathway [3-dehydroquinate (DHQ), 3-dehydroshikimate (DHS),  
 180 shikimate, shikimate 3-phosphate (S3P), and chorismate] significantly accumulated in

181 the T4V-ARO47m strain which remained after complete glycerol consumption (96 h  
 182 fermentation) (Figure 4). In addition, the accumulation of aromatic amino acids [L-Tyr,  
 183 L-phenylalanine (L-Phe), and L-tryptophan (L-Trp)] was maintained at relatively high  
 184 levels in this strain.  
 185



186 **Figure 4. Comparison of intracellular metabolites involved in the resveratrol**  
 187 **synthetic pathway in the T4V, T4V-ARO47m, and their parent strain. Intracellular**  
 188 **metabolites were extracted after 24 and 96 h incubation in YPG medium. Metabolites**


189 extracted from cells were subjected to LC-MS/MS analysis. T4V, T4V-ARO47m, and  
190 their parent strain CBS7435  $\Delta dnl4 \Delta his4$  (Control) were used for intracellular  
191 metabolite analysis. All y-axis units are in n-mol/mg-dry cell weight (DCW). The  
192 dashed arrows indicate multiple enzymatic steps. Error bars represent the standard  
193 deviations of three independent biological samples. Statistical analysis was performed  
194 using EZR (two-tailed, two-sample unequal variance; \* $p < 0.05$ , \*\* $p < 0.005$ ). G6P;  
195 F6P; F1,6BP; GAP; 1,3PG; PEP; 6PGL; 6PG; Ru5P; R5P; Xu5P; S7P; E4P;  
196 DAHP3-deoxy-D-arabino; and EPSP as stated in Figure 1; DHQ: 3-dehydroquinate;  
197 DHS: 3-dehydroshikimate; S3P: shikimate 3-phosphate; L-Tyr: tyrosine; L-Phe:  
198 phenylalanine; L-Trp: tryptophan. N.D.: not detected.

199

## 200 **Expanding the pathway to produce naringenin**

201 A naringenin-producing strain (T4CC strain) was developed by introducing  
202 *HaTAL*, *At4CL*, chalcone synthase from *Hypericum androsaemum* (*HaCHS*), and  
203 chalcone isomerase from *Medicago sativa* (*MsCHI*) into the parent strain (*P. pastoris*  
204 CBS7435  $\Delta dnl4 \Delta his4$ ). Furthermore, *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> were co-overexpressed  
205 in the T4CC strain (T4CC-ARO47m strain). The T4CC-ARO47m strain had a slight  
206 defect on cell growth (Supporting Figure S3) and produced 306 mg/L naringenin  
207 compared with 89 mg/L in the T4CC strain with a yield of 15.3 mg/g-glycerol  
208 consumed (Figure 5A). Fed-batch fermentation with controlled pH and DO in the  
209 T4CC-ARO47m strain produced 1067 mg/L naringenin with a yield of 9.7  
210 mg/g-glycerol consumed after 120 h which was 249% higher than that in flasks (Figure  
211 5B) and is the highest naringenin titer using a microbial host (Supporting Table S1).

212



214 **Figure 5. Naringenin production in the engineered *P. pastoris* strains.** (A) Time  
 215 course of naringenin production and glycerol consumption in YPG culture medium of  
 216 naringenin-producing strains (T4CC and T4CC-ARO47m) and their parent strain  
 217 CBS7435  $\Delta dnl4 \Delta his4$  (Control). Error bars represent standard deviations of three  
 218 independent biological samples. The solid lines and dashed lines represent the  
 219 naringenin titer and glycerol concentration, respectively. (B) Fed-batch fermentation  
 220 results of the T4CC-ARO47m strain using the jar fermenter. The feed was added from  
 221 24 to 96 h. Error bars represent the standard deviations of two independent biological  
 222 samples.


223

#### 224 **Production of BIAs in the engineered strains**

225 A norcoclaurine-producing strain (CDN) was generated by introducing  
 226 *BvCYP<sup>W13L, F309L</sup>*, DOPA decarboxylase from *Pseudomonas putida* (*PpDODC*), and an  
 227 N-terminal truncation of norcoclaurine synthase from *Coptis japonica* ( *$\Delta N$ \_CjNCS*),  
 228 which increases norcoclaurine titer by 50% compared with full-length *CjNCS<sup>7</sup>*.  
 229 *ARO4<sup>K229L</sup>* and *ARO7<sup>G141S</sup>* were co-overexpressed in the CDN strain to produce  
 230 CDN-ARO47m. The CDN-ARO47m strain had a slight defect on cell growth

231 (Supporting Figure S4) and produced 10.6 mg/L norcoclaurine compared with 0.30  
 232 mg/L in the CDN strain (Figure 6A). Fed-batch fermentation with controlled pH and  
 233 DO in the CDN-ARO47m produced 9.7 mg/L norcoclaurine which was comparable  
 234 with batch conditions in flasks (Figure 6B).

235 Reticuline is the last shared intermediate in the major branch point of BIA  
 236 production pathways and is produced from norcoclaurine via four enzymatic steps.  
 237 Therefore, a reticuline-producing strain (CDN-ARO47m\_6CN4 strain) was developed  
 238 by introducing 6-*O*-methyltransferase (*Ps6OMT*), coclaurine *N*-methyltransferase  
 239 (*PsCNMT*), and 4'-*O*-methyltransferase (*Ps4OMT*) from *Papaver somniferum*, and  
 240 *N*-methylcoclaurine hydroxylase from *Eschscholzia californica* (*EcNMCH*) into the  
 241 CDN-ARO47m strain. This strain produced reticuline at a titer of 292  $\mu$ g/L (Figure 6C).  
 242 This is the first report of the successful production of norcoclaurine and reticuline in *P.*



243 *pastoris*.


244 **Figure 6. Production of BIAs (norcoclaurine and reticuline) in the engineered**  
 245 ***P.pastoris* strains.** (A) Time course of norcoclaurine production and glycerol  
 246 consumption in YPG culture medium of norcoclaurine-producing strains (CDN and  
 247 CDN-ARO47m) and their parent strain CBS7435  $\Delta$ *dnl4*  $\Delta$ *his4* (Control). Error bars  
 248 represent the standard deviation of three independent biological samples. The solid lines  
 249 and dashed lines represent norcoclaurine titer and glycerol concentration, respectively.  
 250 (B) Fed-batch fermentation results of CDN-ARO47m using the jar fermenter. The feed

251 was added from 24 to 96 h. Error bars represent the standard deviations of two  
 252 independent biological samples. (C) Time course of reticuline production, glycerol  
 253 consumption, and cell growth (OD<sub>600</sub>) of CDN-ARO47m-6CN4. Error bars represent  
 254 the standard deviations of three independent biological samples.

255

## 256 Production of various aromatic compounds from crude glycerol

257 One of the major challenges in microbial production is the high raw material  
 258 cost. Resveratrol, naringenin, and norcochlorine production were examined using crude  
 259 glycerol by-product from BDF production. Neutralized crude glycerol containing 260.6  
 260 g/L glycerol and 54.6 g/L methanol was diluted to a glycerol concentration of 20 g/L  
 261 and used as a carbon source for batch fermentation with T4V-ARO47m,  
 262 T4CC-ARO47m, and CDN-ARO47m strains. T4V-ARO47m produced 383 mg/L  
 263 resveratrol with a yield of 20.6 mg/g-crude glycerol consumed (Figure 7A),  
 264 T4CC-ARO47m produced 338 mg/L naringenin with a yield of 18.4 mg/g-crude  
 265 glycerol consumed (Figure 7B), and CDN-ARO47m produced 7.1 mg/L norcochlorine  
 266 with a yield of 0.34 mg/g-crude glycerol consumed (Figure 7C). In all fermentations,  
 267 there was little difference in titer, cell growth, and glycerol consumption compared to  
 268 cultivation with pure glycerol indicating that *P. pastoris* is capable of utilizing crude



269 glycerol.

270 **Figure 7. Aromatic compounds production from crude glycerol. (A) Resveratrol, (B)**

271 naringenin, and (C) norcoclaurine production from crude glycerol as a carbon source in  
272 the T4V-ARO47m, T4CC-ARO47m, and CDN-ARO47m strains, respectively. Error  
273 bars represent the standard deviations of three independent biological samples.

274

## 275 **DISCUSSION**

276 Recent synthetic biology improvements indicate that *P. pastoris* is a  
277 promising platform for metabolic engineering and will likely become the  
278 next-generation yeast cell factory<sup>21,24</sup>. Optimization of the biosynthetic pathway for  
279 L-Tyr precursor is essential to achieve high production of various aromatic secondary  
280 metabolites<sup>13,14</sup> (Figure 1).

281 In this study, a fluorescence-based screening system was constructed by  
282 engineering *P. pastoris* to produce betaxanthin to identify the optimal genetic  
283 engineering strategies for high L-Tyr production from glycerol. Overexpression of  
284 *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> from *S. cerevisiae* enhanced L-Tyr titer in *P. pastoris* (Figure  
285 2) with significant accumulation of the intracellular metabolites of the shikimate  
286 pathway (DHQ, DHS, shikimate, S3P, and chorismate) at the beginning of glycerol  
287 consumption (24 h) and at the end (96 h) (Figure 4). Meanwhile, overexpression of PPP  
288 genes *TKL1*, *SOL3*, and *ZWF1* had little positive effect on betaxanthin levels (Figure 2)  
289 which may be caused by the low activity of other PPP enzymes and/or the downstream  
290 shikimate pathway. In yeast, the five-step reaction from  
291 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) to  
292 5-O-(1-carboxyvinyl)-3-phosphoshikimate (EPSP) in the shikimate pathway is catalyzed  
293 by *ARO1*<sup>p29</sup>. The *P. pastoris* *ARO1* overexpressing strain (T4V-ARO47m-ARO1)  
294 increased resveratrol titer by 15% to 544 mg/L (Supporting Figure S5A). However,  
295 *ARO1* overexpression resulted in significant defects in cell growth and glycerol  
296 consumption (Supporting Figure S5B, S5C) which may be caused by excessive flux to  
297 the shikimate pathway resulting in high intracellular toxicity. In other organisms such as



298 plants and bacteria, the five-steps DHAP to EPSP are catalyzed by monofunctional  
299 enzymes. It has been reported that the overexpression of *E. coli* shikimate kinase AroL,  
300 which catalyzes the conversion of shikimate to S3P, enhances the *p*-coumarate titer in *S.*  
301 *cerevisiae*<sup>30</sup>. A similar engineering approach might improve the titer of L-Tyr-derived  
302 compounds in *P. pastoris*.

303 Co-overexpression of *ARO4*<sup>K229L</sup> and *ARO7*<sup>G141S</sup> together with the *de novo*  
304 pathways for the synthesis of resveratrol, naringenin, or norcoclaurine secondary  
305 metabolites increased their titers by 258%, 344%, or 3400%, respectively compared  
306 with the strains introduced only with the heterologous pathway (Figure 3A, 5A, 6A)  
307 using glycerol as the carbon source. Resveratrol titer decreased by approximately half in  
308 resveratrol-producing strains (T4V and T4V-ARO47m) cultured in YPD medium  
309 containing 20 g/L glucose compared with glycerol: the T4V and T4V-ARO47m strain  
310 produced 101 mg/L and 176 mg/L resveratrol, respectively using glucose (Supporting  
311 Figure S6). Cell growth was comparable; however, glycerol was consumed over 96 h,  
312 while glucose was consumed in 48 h (Supporting Figure S2, S6). A similar  
313 phenomenon was reported for resveratrol production using glucose or sucrose carbon  
314 sources in *Scheffersomyces stipitis* engineered to synthesize resveratrol: 237.6 mg/L  
315 resveratrol was produced with 50 g/L glucose consumed in 24 h or 668.6 mg/L  
316 resveratrol was produced and 50 g/L sucrose consumed over 96 h<sup>28</sup>. These results  
317 suggest that the rate of carbon uptake may affect resveratrol production. Further studies  
318 will be needed to elucidate the detailed metabolic mechanisms and physiology of *P.*  
319 *pastoris* by examining differences in intracellular metabolites and protein expression  
320 levels when cultured with glucose or glycerol.

321 In fed-batch fermentation, the resveratrol, naringenin, and norcoclaurine titer  
322 reached 1825 mg/L and 1067 mg/L, and 9.7 mg/L, respectively (Figure 3B, 5B, 6B).  
323 There was little difference in norcoclaurine titer between batch and fed-batch  
324 fermentation (Figure 6A, 6B). The cytoplasmic expression of norcoclaurine synthase

325 (NCS) is toxic to *S. cerevisiae* resulting in reduced norcochlorine and reticuline  
326 production<sup>31</sup>. Toxicity was reduced and reticuline titer increased by the addition of a  
327 peptide tag to the C-terminus (peroxisomal targeting signal type 1, PTS1) of NCS to  
328 compartmentalize NCS into peroxisomes<sup>31</sup>. This approach may be useful for *P. pastoris*.  
329 For better understanding toxicity and productivity of L-Tyr-derived compounds, it will  
330 be important to examine their intracellular accumulation.

331           Crude glycerol by-product from BDF production contains impurities such as  
332 free fatty acids, inorganic salts, and methanol<sup>32,33</sup> and its purification require sequential  
333 treatments including neutralization, distillation, ion exchange, membrane separation,  
334 and activated carbon adsorption<sup>34</sup>. Distillation and ion exchange are energy- and  
335 cost-intensive processes and the total purification cost for commercial production is up  
336 to \$50.45/kg<sup>34,35</sup>. This cost is much higher than the current market price of pure glycerol  
337 (\$1-15/kg)<sup>36</sup> resulting in crude glycerol disposal. Thus, conversion of crude glycerol  
338 into value-added products generates economic and environmental benefits<sup>32,36</sup>. In the  
339 present study, resveratrol, naringenin, and norcochlorine were synthesized using  
340 neutralized crude glycerol to the same levels as that with pure glycerol (Figure 7). This  
341 is the first report of L-Tyr-derived aromatic compound production from crude glycerol  
342 which demonstrates the potential of *P. pastoris* to utilize crude glycerol for the synthesis  
343 of various aromatic compounds.

344           In this study, an L-Tyr chassis was produced to optimize L-Tyr synthesis from  
345 glycerol in *P. pastoris*. A heterologous pathway was introduced into the engineered  
346 strain for the *de novo* production of various L-Tyr-derived aromatic compounds. A  
347 major improvement in the production of aromatic secondary metabolites resveratrol,  
348 naringenin, norcochlorine, and reticuline was observed. This study will accelerate the  
349 development of *P. pastoris* strains capable of producing high value aromatic compounds  
350 from glycerol.

351

## 352 **METHODS**

### 353 **Strains and media conditions**

354 *Escherichia coli* NovaBlue (Merck Millipore, Darmstadt, Germany) was used  
355 for plasmid construction and amplification. The microorganisms were routinely cultured  
356 at 37 °C and 200 rpm in LB medium [10 g/L tryptone (Nacalai Tesque, Kyoto, Japan), 5  
357 g/L yeast extract (Nacalai Tesque), and 5 g/L NaCl] supplemented with 100 µg/mL  
358 ampicillin.

359 The yeast strains used in this study are listed in Table 1. *P. pastoris* CBS7435  
360  $\Delta dnl4 \Delta his4$  was used as a parent strain since it has improved gene targeting efficiency  
361 for homologous recombination<sup>37</sup>. *P. pastoris* strains were cultivated in YPG medium [10  
362 g/L yeast extract, 20 g/L peptone (BD Biosciences, San Jose, CA, USA), and 20 g/L  
363 glycerol], YPD medium [10 g/L yeast extract, 20 g/L peptone, and 20 g/L glucose], or  
364 SD medium [6.7 g/L yeast nitrogen base without amino acids (Difco Laboratories,  
365 Detroit, MI, USA), and 20 g/L glucose] supplemented with 20 mg/L histidine and  
366 appropriate antibiotics including 500 µg/mL G418 (FUJIFILM Wako Pure Chemical,  
367 Osaka, Japan), 300 µg/mL hygromycin (Nacalai Tesque), 100 µg/mL Zeocin (Nacalai  
368 Tesque), and 50 µg/mL clonNAT (Jena Bioscience, Löbstedter, Germany).

369

### 370 **Plasmid construction and yeast strains**

371 Plasmids, synthetic DNA fragments, and primers are listed in Table 1,  
372 Supporting Table S2, and Table S3, respectively. Synthetic DNA fragments of *HaTAL*,  
373 *At4CL*, and *VvVST* were used as previously reported<sup>28</sup>. All other synthetic DNA  
374 fragments were codon-optimized for *P. pastoris* and synthesized by GeneArt (Thermo  
375 Fisher Scientific, Waltham, MA, USA). All plasmids were constructed using the  
376 In-fusion HD cloning kit (Takara Bio USA, Mountain View, CA, USA) according to  
377 the manufacturer's protocol. Detailed methods for plasmid and strain construction are  
378 provided in the supporting information.

379

### 380 **Batch fermentation**

381 Yeast cells were inoculated into 5 mL of YPG medium supplemented with  
382 appropriate antibiotics in test tubes and pre-cultured overnight at 30 °C and 200 rpm.  
383 Cells were centrifuged at 15,000 × *g* for 1 min, washed twice with sterile water,  
384 inoculated in 20 mL YPG medium in 100-mL Erlenmeyer flasks with a cap-type plug at  
385 an initial OD<sub>600</sub> of 0.05, and cultivated at 30 °C and 150 rpm in an orbital shaker  
386 incubator (BR-43FL; Taitec, Saitama, Japan). The culture broth was used to measure  
387 OD<sub>600</sub> and the concentration of glucose, glycerol, resveratrol, naringenin, norcochlorine,  
388 reticuline, and intracellular metabolites was measured as described below.

389

### 390 **Fluorescence-based screening with betaxanthin**

391 Yeast cells were centrifuged at 15,000 × *g* for 1 min after 24 h cultivation in  
392 YPG medium as described above. Two hundred and fifty μL of culture supernatant was  
393 transferred to a 96-well black plate (Sumitomo Bakelite, Tokyo, Japan) and  
394 fluorescence intensity was measured using an excitation wavelength of 485 nm and  
395 emission wavelength of 510 nm to determine betaxanthin levels using Envision 2014  
396 multilabel plate reader (PerkinElmer, Waltham, MA, USA).

397

### 398 **Fed-batch fermentation in jar fermenter**

399 Yeast cells were pre-cultured in 20 mL of YPG medium supplemented with  
400 appropriate antibiotics in a 100-mL Erlenmeyer flask at 30 °C and 150 rpm for 48 h.  
401 Cells in stationary phase were centrifuged at 5,000 × *g* for 5 min, washed twice with  
402 sterile water, suspended in 100 mL YPG medium and transferred into a 250-mL jar  
403 fermenter (Bio Jr. 8; ABLE Biott, Tokyo, Japan) at an initial OD<sub>600</sub> of 5.0. Fermentation  
404 was carried out at 30 °C and the airflow was maintained at 100 mL/min. The pH of the  
405 culture medium was maintained at 5.5 by the automatic addition of a 5 N ammonium

406 solution, and antifoam SI (FUJIFILM Wako Pure Chemical, Osaka, Japan) was added in  
407 the range of 0.01-0.1 %. The agitation speed varied between 300 and 600 rpm to  
408 maintain dissolved oxygen (DO) at 20%. A feeding solution composed of 50 g/L yeast  
409 extract, 100 g/L peptone, and 200 g/L glycerol was pumped into the jar fermenter at a  
410 flow rate of 625  $\mu$ L/h (45 mL total volume) after 24 h fermentation. Approximately 1  
411 mL samples were withdrawn every 24 h to measure OD<sub>600</sub> and the concentration of  
412 glycerol, resveratrol, naringenin, and norcoclaurine.

413

#### 414 **Purification of crude glycerol**

415 Crude glycerol, a major by-product from the biodiesel industry, was kindly  
416 provided by the Sannokura Center (Gifu, Japan) and pretreated according to the method  
417 described by Chi et al<sup>38</sup>. Briefly, the pH of crude glycerol was adjusted to 6.3 with 1 N  
418 HCl, stirred for 2 h at room temperature, added to a separatory funnel, and the lower  
419 layer collected and filtered through a 0.22  $\mu$ m filter. The glycerol and methanol  
420 concentrations in the filtered liquid was analyzed as described below. The filtered liquid  
421 was diluted with sterile water to a final glycerol concentration of 20 g/L together with  
422 10 g/L yeast extract and 20 g/L peptone in the culture medium. Batch fermentation was  
423 performed using the same conditions as described above.

424

#### 425 **Analytical methods**

426 The concentrations of glucose, glycerol, and methanol were analyzed by  
427 high-performance liquid chromatography (HPLC) (Shimadzu, Kyoto, Japan) equipped  
428 with an Aminex HPX-87H column (7.8 mm  $\times$  300 mm, 9  $\mu$ m particle size; Bio-Rad,  
429 Hercules, CA, USA) and a RID-10A refractive index detector (Shimadzu). The column  
430 was kept at 65  $^{\circ}$ C, and 5 mM H<sub>2</sub>SO<sub>4</sub> was used as the mobile phase at a flow rate of 0.6  
431 mL/min. For resveratrol and naringenin quantification, culture samples were mixed with  
432 an equal volume of 100% ethanol, vortexed for 10 s, and centrifugated at 15,000  $\times$  g for

433 5 min at room temperature<sup>28,39</sup>. These supernatants were then analyzed by HPLC  
 434 equipped with a Luna Omega PS C18 column (4.6 × 150 mm, 3 μm particle size;  
 435 Phenomenex, CA, USA) as described previously<sup>28</sup>. Quantification of norcoclaurine and  
 436 reticuline in the fermentation medium was carried out with an LCMS-8060 triple  
 437 quadrupole mass spectrometer (Shimadzu) equipped with a Discovery HS F5-3 column  
 438 (2.1 mm × 150 mm, 3 μm, Sigma-Aldrich, MO, USA) using previously described  
 439 running conditions<sup>40</sup>.

440

#### 441 **Intracellular metabolite analysis**

442 The extraction method for intracellular metabolites followed a previously  
 443 described method<sup>41</sup>. Intracellular metabolites related to amino acids and the shikimate  
 444 pathway were analyzed using the LCMS-8060 instrument described above. Metabolites  
 445 related to glycolysis and PPP were analyzed using a 6460 Triple Quad LC/MS (Agilent  
 446 Technologies, CA, USA) equipped with a Mastro C18 column (2.1 mm × 150 mm, 3  
 447 μm, Shimadzu) using previously described running conditions<sup>40,42</sup>.

448

#### 449 **Statistical analysis**

450 All numerical values are depicted as the means ± s.d. One-way ANOVA was  
 451 used as a statistical test in conjunction with Tukey's range test to assess significant  
 452 differences between strains. Statistical analysis was performed using EZR<sup>43</sup> which is a  
 453 modified version of R commander designed to add frequently used statistical functions  
 454 in biostatistics (two-tailed, two-sample unequal variance; \* $p < 0.05$ , \*\* $p < 0.005$ ).

455

**Table 1 Yeast strains and plasmids**

Strains	Description	Source
CBS7435 <i>Δdnl4 Δhis4</i>	<i>Δdnl4 Δhis4</i> :: ADE1	<sup>37</sup>
CD	CBS7435 <i>Δdnl4 Δhis4</i> / pPGP-CYP-DOD [G418 <sup>r</sup> ]	This study
CD-TKL1	CD / pPGPZ-TKL1 [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study

CD-SOL3	CD / pPGPZ-SOL3 [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
CD-ZWF1	CD / pPGPZ-ZWF1 [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
CD-SOL3-ZWF1	CD / pPGPZ-SOL3-ZWF1 [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
CD-ARO4m	CD / pPGPH-ARO4 <sup>K229L</sup> [G418 <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CD-ARO7m	CD / pPGPZ-ARO7 <sup>G141S</sup> [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
CD47m	CD / pPGPH-ARO4 <sup>K229L</sup> -ARO7 <sup>G141S</sup> [G418 <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CD47m-TKL1	CD47m / pPGPZ-TKL1 [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CD47m-SOL3	CD47m / pPGPZ-SOL3 [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CD47m-ZWF1	CD47m / pPGPZ-ZWF1 [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CD47m-SOL3-ZWF1	CD47m / pPGPZ-SOL3-ZWF1 [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
T4V	CBS7435 <i>Δdn14 Δhis4</i> / pPGP-TAL-4CL-VST [G418 <sup>r</sup> ]	This study
T4V-ARO47m	T4V / pPGPH-ARO4 <sup>K229L</sup> -ARO7 <sup>G141S</sup> [G418 <sup>r</sup> , Hyg <sup>r</sup> ]	This study
T4CC	CBS7435 <i>Δdn14 Δhis4</i> / pPGP-TAL-4CL, pPGPZ-CHS-CHI [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
T4CC-ARO47m	T4CC / pPGPH-ARO4 <sup>K229L</sup> -ARO7 <sup>G141S</sup> [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CDN	CBS7435 <i>Δdn14 Δhis4</i> / pPGP-CYP-DODC, pPGPZ-NCS [G418 <sup>r</sup> , Zeo <sup>r</sup> ]	This study
CDN-ARO47m	CDN / pPGPH-ARO4 <sup>K229L</sup> -ARO7 <sup>G141S</sup> [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> ]	This study
CDN-ARO47m-6CN4	CDN-ARO47m / pPHU-6OMT-CNMT, pPNS-NMCH-4OMT [G418 <sup>r</sup> , Zeo <sup>r</sup> , Hyg <sup>r</sup> , NAT <sup>r</sup> , <i>his4</i> ]	This study

---

### Plasmids

---

pPGP-EGFP	G418 <sup>r</sup> , <i>P<sub>gap</sub>-EGFP-T<sub>aox1</sub></i>	37
pPGP-CYP	G418 <sup>r</sup> , <i>P<sub>gap</sub>-BvCYP<sup>W13L, F309L</sup>-T<sub>aox1</sub></i>	44
pPGPH-DOD	Hyg <sup>r</sup> , <i>P<sub>gap</sub>-MjDOD-T<sub>aox1</sub></i>	44
pPGPZ-EGFP	Zeo <sup>r</sup> , <i>P<sub>gap</sub>-EGFP-T<sub>aox1</sub></i>	This study
pPGP-CYP-DOD	G418 <sup>r</sup> , <i>P<sub>gap</sub>-BvCYP<sup>W13L, F309L</sup>-T<sub>aox1</sub></i> ,	This study

	<i>P<sub>gap</sub>-MjDOD-T<sub>aox1</sub></i>	
pPGPZ-TKL1	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-TKL1-T<sub>aox1</sub></i>	This study
pPGPZ-SOL3	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-SOL3-T<sub>aox1</sub></i>	This study
pPGPZ-ZWF1	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-ZWF1-T<sub>aox1</sub></i>	This study
pPGPZ-SOL3-ZWF1	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-SOL3-T<sub>aox1</sub>, P<sub>gap</sub>-ZWF1-T<sub>aox1</sub></i>	This study
pPGPH-ARO4 <sup>K229L</sup>	<i>Hyg<sup>r</sup>, P<sub>gap</sub>-ARO4<sup>K229L</sup>-T<sub>aox1</sub></i>	This study
pPGPZ-ARO7 <sup>G141S</sup>	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-ARO7<sup>G141S</sup>-T<sub>aox1</sub></i>	This study
pPGPH-ARO4 <sup>K229L</sup> -ARO7 <sup>G141S</sup>	<i>Hyg<sup>r</sup>, P<sub>gap</sub>-ARO4<sup>K229L</sup>-T<sub>aox1</sub>, P<sub>gap</sub>-ARO7<sup>G141S</sup>-T<sub>aox1</sub></i>	This study
pPGPZ-ARO1	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-ARO1-T<sub>aox1</sub></i>	This study
pPGP-TAL	<i>G418<sup>r</sup>, P<sub>gap</sub>-HaTAL-T<sub>aox1</sub>,</i>	This study
pPGP-4CL	<i>G418<sup>r</sup>, P<sub>gap</sub>-At4CL-T<sub>aox1</sub>,</i>	This study
pPGPZ-VST	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-VvVST-T<sub>aox1</sub></i>	This study
pPGP-TAL-VST	<i>G418<sup>r</sup>, P<sub>gap</sub>-HaTAL-T<sub>aox1</sub>, P<sub>gap</sub>-VvVST-T<sub>aox1</sub></i>	This study
pPGP-TAL-4CL-VST	<i>G418<sup>r</sup>, P<sub>gap</sub>-HaTAL-T<sub>aox1</sub>, P<sub>gap</sub>-At4CL-T<sub>aox1</sub></i>	This study
	<i>P<sub>gap</sub>-VvVST-T<sub>aox1</sub>,</i>	
pPGP-TAL-4CL	<i>G418<sup>r</sup>, P<sub>gap</sub>-HaTAL-T<sub>aox1</sub>, P<sub>gap</sub>-At4CL-T<sub>aox1</sub></i>	This study
pPGPZ-CHS	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-HaCHS-T<sub>aox1</sub></i>	This study
pPGPZ-CHI	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-MsCHI-T<sub>aox1</sub></i>	This study
pPGPZ-CHS-CHI	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-HaCHS-T<sub>aox1</sub>, P<sub>gap</sub>-MsCHI-T<sub>aox1</sub></i>	This study
pPHU	<i>HIS4</i> marker,	This study
pPNS	<i>NAT<sup>r</sup></i>	This study
pPGPZ-DODC	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-PpDODC-T<sub>aox1</sub></i>	This study
pPGP-CYP-DODC	<i>G418<sup>r</sup>, P<sub>gap</sub>-BvCYP<sup>W13L, F309L</sup>-T<sub>aox1</sub>,</i>	This study
	<i>P<sub>gap</sub>-PpDODC-T<sub>aox1</sub></i>	
pPGPZ-NCS	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-ΔN_CjNCS-T<sub>aox1</sub></i>	This study
pPGPZ-6OMT	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-Ps6OMT-T<sub>aox1</sub></i>	This study
pPGPZ-CNMT	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-PsCNMT-T<sub>aox1</sub></i>	This study
pPGPZ-NMCH	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-EcNMCH-T<sub>aox1</sub></i>	This study
pPGPZ-4OMT	<i>Zeo<sup>r</sup>, P<sub>gap</sub>-Ps4OMT-T<sub>aox1</sub></i>	This study
pPHU-6OMT	<i>HIS4</i> marker, <i>P<sub>gap</sub>-Ps6OMT-T<sub>aox1</sub></i>	This study
pPHU-6OMT-CNMT	<i>HIS4</i> marker, <i>P<sub>gap</sub>-Ps6OMT-T<sub>aox1</sub>,</i>	This study



	<i>P<sub>gap</sub>-PsCNMT-T<sub>aox1</sub></i>	
pPNS-NMCH	NAT <sup>r</sup> , <i>P<sub>gap</sub>-EcNMCH-T<sub>aox1</sub></i>	This study
pPNS-NMCH-4OMT	NAT <sup>r</sup> , <i>P<sub>gap</sub>-EcNMCH-T<sub>aox1</sub></i> , <i>P<sub>gap</sub>-Ps4OMT-T<sub>aox1</sub></i>	This study

---

456

## 457 ASSOCIATED CONTENT

### 458 Supporting Information

459 Detailed methods for plasmid and yeast strain construction; Supporting Figure S1,  
 460 Difference in yeast colony coloration and green fluorescence for  
 461 betaxanthin-producing cells; Supporting Figure S2-S4, Cell growth of engineered  
 462 strains; Supporting Figure S5, The data of resveratrol production in ARO1  
 463 overexpressing strain; Supporting Figure S6, The data of resveratrol production  
 464 using glucose; Supporting Table S1, Comparison of resveratrol, naringenin,  
 465 norcochlorine, and reticuline titer by various microbial hosts; Supporting Table S2,  
 466 Synthetic DNA fragments; Supporting Table S3, Primer list.

467

## 468 AUTHOR INFORMATION

### 469 Corresponding Author

470 **Tomohisa Hasunuma** —Engineering Biology Research Center, Kobe University,  
 471 1-1 Rokkodai, Nada, Kobe, 657-8501, Japan; [orcid.org/0000-0002-8382-2362](https://orcid.org/0000-0002-8382-2362);  
 472 Phone: +81-78-803-6461;  
 473 E-mail: [hasunuma@port.kobe-u.ac.jp](mailto:hasunuma@port.kobe-u.ac.jp); Fax: +81-78-803-6461

474

### 475 Authors

476 **Ryota KUMOKITA** — Graduate School of Science, Technology and Innovation,  
 477 Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

478 **Takahiro Bamba** — Graduate School of Science, Technology and Innovation,  
 479 Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

480 **Kentaro Inokuma** — Graduate School of Science, Technology and Innovation,  
481 Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

482 **Takanobu Yoshida** — Graduate School of Science, Technology and Innovation,  
483 Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

484 **Yoichiro Ito** — Graduate School of Science, Technology and Innovation, Kobe  
485 University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

486 **Akihiko Kondo** — Graduate School of Science, Technology and Innovation, Kobe  
487 University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

488

#### 489 **Authorship Contributions**

490 R. K. and T. B. conceived the topic and designed the study. R. K. performed all genetic  
491 engineering and fermentation experiments. T. Y. analyzed the data. All authors  
492 discussed the results. R. K. wrote the manuscript supported from T.B., K. I., and T. H.  
493 Y. I., A. K., and T. H. supervised all aspects of the study.

494

#### 495 **Notes**

496 The authors declare no conflict of interest.

497

#### 498 **ACKNOWLEDGEMENTS**

499 The authors are grateful for support from the NEDO project P16009 (Development of  
500 production techniques for highly functional biomaterials using plant and other organism  
501 smart cells) and P20011 (Development of bio-derived product production technology  
502 that accelerates the realization of carbon recycling).

503

504

505

506 **REFERENCES**

- 507 (1) Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs from  
508 1981 to 2014. *J. Nat. Prod.* **2016**, *79* (3), 629–661.  
509 <https://doi.org/10.1021/acs.jnatprod.5b01055>.
- 510 (2) Navarro, G.; Martínez Pinilla, E.; Ortiz, R.; Noé, V.; Ciudad, C. J.; Franco, R.  
511 Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with  
512 Health-Promoting Actions: Industrial Production, Safety, and the Search for  
513 Mode of Action. *Compr. Rev. Food Sci. Food Saf.* **2018**, *17* (4), 808–826.  
514 <https://doi.org/10.1111/1541-4337.12359>.
- 515 (3) Milke, L.; Aschenbrenner, J.; Marienhagen, J.; Kallscheuer, N. Production of  
516 Plant-Derived Polyphenols in Microorganisms: Current State and Perspectives.  
517 *Appl. Microbiol. Biotechnol.* **2018**, *102* (4), 1575–1585.  
518 <https://doi.org/10.1007/s00253-018-8747-5>.
- 519 (4) Facchini, P. J.; Bohlmann, J.; Covello, P. S.; Luca, V. De; Mahadevan, R.; Page,  
520 J. E.; Ro, D.; Sensen, C. W.; Storms, R.; Martin, V. J. J. Synthetic Biosystems for  
521 the Production of High-Value Plant Metabolites. *Trends Biotechnol.* **2012**, *30* (3),  
522 127–131. <https://doi.org/10.1016/j.tibtech.2011.10.001>.
- 523 (5) Glenn, W. S.; Runguphan, W.; Connor, S. E. O. Recent Progress in the Metabolic  
524 Engineering of Alkaloids in Plant Systems. *Curr. Opin. Biotechnol.* **2013**, *24* (2),  
525 354–365. <https://doi.org/10.1016/j.copbio.2012.08.003>.
- 526 (6) Pyne, M. E.; Narcross, L.; Martin, V. J. J. Engineering Plant Secondary  
527 Metabolism in Microbial Systems. *Plant Physiol.* **2019**, *179* (3), 844–861.  
528 <https://doi.org/10.1104/pp.18.01291>.
- 529 (7) Pyne, M. E.; Kevvai, K.; Grewal, P. S.; Narcross, L.; Choi, B.; Bourgeois, L.;  
530 Dueber, J. E.; Martin, V. J. J. A Yeast Platform for High-Level Synthesis of  
531 Tetrahydroisoquinoline Alkaloids. *Nat. Commun.* **2020**, *11* (1), 1–10.

- 532 <https://doi.org/10.1038/s41467-020-17172-x>.
- 533 (8) Zhou, S.; Hao, T.; Zhou, J. Fermentation and Metabolic Pathway Optimization to  
534 de Novo Synthesize (2S)-Naringenin in Escherichia Coli. *J. Microbiol.*  
535 *Biotechnol.* **2020**, *30* (10), 1574–1582. <https://doi.org/10.4014/JMB.2008.08005>.
- 536 (9) Cravens, A.; Payne, J.; Smolke, C. D. Synthetic Biology Strategies for Microbial  
537 Biosynthesis of Plant Natural Products. *Nat. Commun.* **2019**, *10* (1), 1–12.  
538 <https://doi.org/10.1038/s41467-019-09848-w>.
- 539 (10) Yuan, S. F.; Alper, H. S. Metabolic Engineering of Microbial Cell Factories for  
540 Production of Nutraceuticals. *Microb. Cell Fact.* **2019**, *18* (1), 1–11.  
541 <https://doi.org/10.1186/s12934-019-1096-y>.
- 542 (11) Suástegui, M.; Shao, Z. Yeast Factories for the Production of Aromatic  
543 Compounds: From Building Blocks to Plant Secondary Metabolites. *J. Ind.*  
544 *Microbiol. Biotechnol.* **2016**, *43* (11), 1611–1624.  
545 <https://doi.org/10.1007/s10295-016-1824-9>.
- 546 (12) Gottardi, M.; Reifenrath, M.; Boles, E.; Tripp, J. Pathway Engineering for the  
547 Production of Heterologous Aromatic Chemicals and Their Derivatives in  
548 *Saccharomyces Cerevisiae*: Bioconversion from Glucose. *FEMS Yeast Res.* **2017**,  
549 *17* (4), 1–11. <https://doi.org/10.1093/femsyr/fox035>.
- 550 (13) Liu, Q.; Liu, Y.; Chen, Y.; Nielsen, J. Current State of Aromatics Production  
551 Using Yeast: Achievements and Challenges. *Curr. Opin. Biotechnol.* **2020**, *65*,  
552 65–74. <https://doi.org/10.1016/j.copbio.2020.01.008>.
- 553 (14) Rajkumar, A. S.; Morrissey, J. P. Rational Engineering of *Kluyveromyces*  
554 *Marxianus* to Create a Chassis for the Production of Aromatic Products. *Microb.*  
555 *Cell Fact.* **2020**, *19* (1), 1–19. <https://doi.org/10.1186/s12934-020-01461-7>.
- 556 (15) Krivoruchko, A.; Nielsen, J. Production of Natural Products through Metabolic  
557 Engineering of *Saccharomyces Cerevisiae*. *Curr. Opin. Biotechnol.* **2015**, *35*,  
558 7–15. <https://doi.org/10.1016/j.copbio.2014.12.004>.

- 559 (16) Narcross, L.; Fossati, E.; Bourgeois, L.; Dueber, J. E.; Martin, V. J. J. Microbial  
560 Factories for the Production of Benzylisoquinoline Alkaloids. *Trends Biotechnol.*  
561 **2016**, *34* (3), 228–241. <https://doi.org/10.1016/j.tibtech.2015.12.005>.
- 562 (17) Li, Y.; Mao, J.; Liu, Q.; Song, X.; Wu, Y.; Cai, M.; Xu, H.; Qiao, M. De Novo  
563 Biosynthesis of Caffeic Acid from Glucose by Engineered *Saccharomyces*  
564 *Cerevisiae*. *ACS Synth. Biol.* **2020**, *9* (4), 756–765.  
565 <https://doi.org/10.1021/acssynbio.9b00431>.
- 566 (18) Patra, P.; Das, M.; Kundu, P.; Ghosh, A. Recent Advances in Systems and  
567 Synthetic Biology Approaches for Developing Novel Cell-Factories in  
568 Non-Conventional Yeasts. *Biotechnol. Adv.* **2021**, *47* (December 2020), 107695.  
569 <https://doi.org/10.1016/j.biotechadv.2021.107695>.
- 570 (19) Palmer, C. M.; Miller, K. K.; Nguyen, A.; Alper, H. S. Engineering  
571 4-Coumaroyl-CoA Derived Polyketide Production in *Yarrowia Lipolytica*  
572 through a  $\beta$ -Oxidation Mediated Strategy. *Metab. Eng.* **2020**, *57* (November  
573 2019), 174–181. <https://doi.org/10.1016/j.ymben.2019.11.006>.
- 574 (20) Sáez-Sáez, J.; Wang, G.; Marella, E. R.; Sudarsan, S.; Cernuda Pastor, M.;  
575 Borodina, I. Engineering the Oleaginous Yeast *Yarrowia Lipolytica* for  
576 High-Level Resveratrol Production. *Metab. Eng.* **2020**, *62* (April), 51–61.  
577 <https://doi.org/10.1016/j.ymben.2020.08.009>.
- 578 (21) Yang, Z.; Zhang, Z. Engineering Strategies for Enhanced Production of Protein  
579 and Bio-Products in *Pichia Pastoris*: A Review. *Biotechnol. Adv.* **2018**, *36* (1),  
580 182–195. <https://doi.org/10.1016/j.biotechadv.2017.11.002>.
- 581 (22) Wen, J.; Tian, L.; Liu, Q.; Zhang, Y.; Cai, M. Engineered Dynamic Distribution  
582 of Malonyl-CoA Flux for Improving Polyketide Biosynthesis in *Komagataella*  
583 *Phaffii*. *J. Biotechnol.* **2020**, *320* (April), 80–85.  
584 <https://doi.org/10.1016/j.jbiotec.2020.06.012>.
- 585 (23) Hagman, A.; Säll, T.; Piškur, J. Analysis of the Yeast Short-Term Crabtree Effect

- 586 and Its Origin. *FEBS J.* **2014**, *281* (21), 4805–4814.  
587 <https://doi.org/10.1111/febs.13019>.
- 588 (24) Peña, D. A.; Gasser, B.; Zanghellini, J.; Steiger, M. G.; Mattanovich, D.  
589 Metabolic Engineering of *Pichia Pastoris*. *Metab. Eng.* **2018**, *50* (February), 2–15.  
590 <https://doi.org/10.1016/j.ymben.2018.04.017>.
- 591 (25) Mattanovich, D.; Graf, A.; Stadlmann, J.; Dragosits, M.; Redl, A.; Maurer, M.;  
592 Kleinheinz, M.; Sauer, M.; Altmann, F.; Gasser, B. Genome, Secretome and  
593 Glucose Transport Highlight Unique Features of the Protein Production Host  
594 *Pichia Pastoris*. *Microb. Cell Fact.* **2009**, *8*, 1–13.  
595 <https://doi.org/10.1186/1475-2859-8-29>.
- 596 (26) Palmerín-Carreño, D.; Martínez-Alarcón, D.; Dena-Beltrán, J. L.; Vega-Rojas, L.  
597 J.; Blanco-Labra, A.; Escobedo-Reyes, A.; García-Gasca, T. Optimization of a  
598 Recombinant Lectin Production in *Pichia Pastoris* Using Crude Glycerol in a  
599 Fed-Batch System. *Processes* **2021**, *9* (5). <https://doi.org/10.3390/pr9050876>.
- 600 (27) Nocon, J.; Steiger, M.; Mairinger, T.; Hohlweg, J.; Rußmayer, H.; Hann, S.;  
601 Gasser, B.; Mattanovich, D. Increasing Pentose Phosphate Pathway Flux  
602 Enhances Recombinant Protein Production in *Pichia Pastoris*. *Appl. Microbiol.*  
603 *Biotechnol.* **2016**, *100* (13), 5955–5963.  
604 <https://doi.org/10.1007/s00253-016-7363-5>.
- 605 (28) Kobayashi, Y.; Inokuma, K.; Matsuda, M.; Kondo, A.; Hasunuma, T. Resveratrol  
606 Production from Several Types of Saccharide Sources by a Recombinant  
607 *Scheffersomyces Stipitis* Strain. *Metab. Eng. Commun.* **2021**, *13* (October),  
608 e00188. <https://doi.org/10.1016/j.mec.2021.e00188>.
- 609 (29) Liu, Q.; Yu, T.; Li, X.; Chen, Y.; Campbell, K.; Nielsen, J.; Chen, Y. Rewiring  
610 Carbon Metabolism in Yeast for High Level Production of Aromatic Chemicals.  
611 *Nat. Commun.* **2019**, *10* (1), 1–13. <https://doi.org/10.1038/s41467-019-12961-5>.
- 612 (30) Rodriguez, A.; Kildegaard, K. R.; Li, M.; Borodina, I.; Nielsen, J. Establishment

- 613 of a Yeast Platform Strain for Production of P-Coumaric Acid through Metabolic  
614 Engineering of Aromatic Amino Acid Biosynthesis. *Metab. Eng.* **2015**, *31*,  
615 181-188. <https://doi.org/10.1016/j.ymben.2015.08.003>.
- 616 (31) Grewal, P. S.; Samson, J. A.; Baker, J. J.; Choi, B.; Dueber, J. E. Peroxisome  
617 Compartmentalization of a Toxic Enzyme Improves Alkaloid Production. *Nat.*  
618 *Chem. Biol.* **2021**, *17* (1), 96–103. <https://doi.org/10.1038/s41589-020-00668-4>.
- 619 (32) Luo, Z.; Miao, J.; Luo, W.; Li, G.; Du, Y.; Yu, X. Crude Glycerol from Biodiesel  
620 as a Carbon Source for Production of a Recombinant Highly Thermostable  
621  $\beta$ -Mannanase by *Pichia Pastoris*. *Biotechnol. Lett.* **2018**, *40* (1), 135–141.  
622 <https://doi.org/10.1007/s10529-017-2451-x>.
- 623 (33) Do, D. T. H.; Theron, C. W.; Fickers, P. Organic Wastes as Feedstocks for  
624 Non-Conventional Yeast-Based Bioprocesses. *Microorganisms* **2019**, *7* (8), 1–22.  
625 <https://doi.org/10.3390/microorganisms7080229>.
- 626 (34) Ardi, M. S.; Aroua, M. K.; Hashim, N. A. Progress, Prospect and Challenges in  
627 Glycerol Purification Process: A Review. *Renew. Sustain. Energy Rev.* **2015**, *42*,  
628 1164–1173. <https://doi.org/10.1016/j.rser.2014.10.091>.
- 629 (35) Chol, C. G.; Dhabhai, R.; Dalai, A. K.; Reaney, M. Purification of Crude  
630 Glycerol Derived from Biodiesel Production Process: Experimental Studies and  
631 Techno-Economic Analyses. *Fuel Process. Technol.* **2018**, *178* (May), 78–87.  
632 <https://doi.org/10.1016/j.fuproc.2018.05.023>.
- 633 (36) Kumar, L. R.; Kaur, R.; Tyagi, R. D.; Drogui, P. Identifying Economical Route  
634 for Crude Glycerol Valorization: Biodiesel versus Polyhydroxy-Butyrate (PHB).  
635 *Bioresour. Technol.* **2021**, *323* (December 2020), 124565.  
636 <https://doi.org/10.1016/j.biortech.2020.124565>.
- 637 (37) Ito, Y.; Watanabe, T.; Aikawa, S.; Nishi, T.; Nishiyama, T.; Nakamura, Y.;  
638 Hasunuma, T.; Okubo, Y.; Ishii, J.; Kondo, A. Deletion of DNA Ligase IV  
639 Homolog Confers Higher Gene Targeting Efficiency on Homologous

- 640 Recombination in *Komagataella Phaffii*. *FEMS Yeast Res.* **2018**, *18* (7), 1–9.  
641 <https://doi.org/10.1093/femsyr/foy074>.
- 642 (38) Chi, Z.; Pyle, D.; Wen, Z.; Frear, C.; Chen, S. A Laboratory Study of Producing  
643 Docosahexaenoic Acid from Biodiesel-Waste Glycerol by Microalgal  
644 Fermentation. *Process Biochem.* **2007**, *42* (11), 1537–1545.  
645 <https://doi.org/10.1016/j.procbio.2007.08.008>.
- 646 (39) Li, M.; Schneider, K.; Kristensen, M.; Borodina, I.; Nielsen, J. Engineering Yeast  
647 for High-Level Production of Stilbenoid Antioxidants. *Sci. Rep.* **2016**, *6*, 1–8.  
648 <https://doi.org/10.1038/srep36827>.
- 649 (40) Vavricka, C. J.; Yoshida, T.; Kuriya, Y.; Takahashi, S.; Ogawa, T.; Ono, F.;  
650 Agari, K.; Kiyota, H.; Li, J.; Ishii, J.; Tsuge, K.; Minami, H.; Araki, M.;  
651 Hasunuma, T.; Kondo, A. Mechanism-Based Tuning of Insect  
652 3,4-Dihydroxyphenylacetaldehyde Synthase for Synthetic Bioproduction of  
653 Benzylisoquinoline Alkaloids. *Nat. Commun.* **2019**, *10* (1), 1–11.  
654 <https://doi.org/10.1038/s41467-019-09610-2>.
- 655 (41) Kato, H.; Izumi, Y.; Hasunuma, T.; Matsuda, F.; Kondo, A. Widely Targeted  
656 Metabolic Profiling Analysis of Yeast Central Metabolites. *J. Biosci. Bioeng.*  
657 **2012**, *113* (5), 665–673. <https://doi.org/10.1016/j.jbiosc.2011.12.013>.
- 658 (42) Hsu, H. H.; Araki, M.; Mochizuki, M.; Hori, Y.; Murata, M.; Kahar, P.; Yoshida,  
659 T.; Hasunuma, T.; Kondo, A. A Systematic Approach to Time-Series Metabolite  
660 Profiling and RNA-Seq Analysis of Chinese Hamster Ovary Cell Culture. *Sci.*  
661 *Rep.* **2017**, *7* (March), 1–13. <https://doi.org/10.1038/srep43518>.
- 662 (43) Kanda, Y. Investigation of the Freely Available Easy-to-Use Software “EZR” for  
663 Medical Statistics. *Bone Marrow Transplant.* **2013**, *48* (3), 452–458.  
664 <https://doi.org/10.1038/bmt.2012.244>.
- 665 (44) Ito, Y.; Terai, G.; Ishigami, M.; Hashiba, N.; Nakamura, Y.; Bamba, T.;  
666 Kumokita, R.; Hasunuma, T.; Asai, K.; Ishii, J.; Kondo, A. Exchange of



667 Endogenous and Heterogeneous Yeast Terminators in *Pichia Pastoris* to Tune  
668 mRNA Stability and Gene Expression. *Nucleic Acids Res.* **2020**, *48* (22),  
669 13000–13012. <https://doi.org/10.1093/nar/gkaa1066>.  
670